公开(公告)号：US20250129063A1

公开(公告)日：2025-04-24

申请号：US18913711

申请日：2024-10-11

Applicant: Genentech, Inc.

Inventor： Jakob FUHRMANN ,  Alberto Emilio GOBBI ,  Joachim RUDOLPH

IPC: C07D417/14 ,  A61K31/428 ,  A61K45/06 ,  A61K47/55

Abstract: The present disclosure relates to benzothiazole compounds and to methods of using such compounds. The present disclosure further relates to the use of the compounds described herein, or pharmaceutical compositions thereof, to prevent and/or treat a range of diseases, disorders, and conditions.

公开(公告)号：US20240383897A1

公开(公告)日：2024-11-21

申请号：US18604314

申请日：2024-03-13

Applicant: Genentech, Inc.

Inventor： Elisia VILLEMURE ,  Joachim RUDOLPH ,  Mingshuo ZENG

IPC: C07D471/08 ,  C07D471/10 ,  C07D487/14

Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.

公开(公告)号：US20230112485A1

公开(公告)日：2023-04-13

申请号：US17883004

申请日：2022-08-08

Applicant: Genentech, Inc.

Inventor： Elisia VILLEMURE ,  Joachim RUDOLPH ,  Mingshuo ZENG

IPC: C07D471/08 ,  C07D471/10 ,  C07D487/14

Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.

公开(公告)号：US20140323477A1

公开(公告)日：2014-10-30

申请号：US14266617

申请日：2014-04-30

Applicant: Genentech, Inc.

Inventor： James J. CRAWFORD ,  Wendy LEE ,  Joachim RUDOLPH

IPC: C07D471/04 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/519

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06

Abstract: Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, and Ar are as defined herein, are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders using such compounds.

Abstract translation: 具有式I的化合物或其药学上可接受的盐，其中R 1，R 2，X 1，X 2和Ar如本文所定义，是PAK1的抑制剂。 还公开了使用这些化合物治疗癌症和过度增殖性疾病的组合物和方法。